Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George S Laszlo

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
The Journal of Biological Chemistry|May 24, 2003
Src family kinase-independent signal transduction and gene induction by leukemia inhibitory factorGeorge S Laszlo, Neil M Nathanson
Current Biology : CB|January 17, 2009
Restriction of Src activity by Cullin-5George S Laszlo, Jonathan A Cooper
Journal of Neurochemistry|July 16, 2008
Transregulation of leukemia inhibitory [corrected] factor receptor expression and function by growth factors in neuroblastoma cellsMartha D Port, George S Laszlo, Neil M Nathanson
Blood Reviews|May 10, 2014
The past and future of CD33 as therapeutic target in acute myeloid leukemiaGeorge S Laszlo, Elihu H Estey, Roland B Walter
Biochimica Et Biophysica Acta|July 23, 2005
Calmodulin-dependent protein kinases phosphorylate gp130 at the serine-based dileucine internalization motifRobin M Gibson, George S Laszlo, Neil M Nathanson
Journal of Neurochemistry|June 28, 2006
Multiple promoter elements required for leukemia inhibitory factor-stimulated M2 muscarinic acetylcholine receptor promoter activityGeorge S Laszlo, Marc L Rosoff, Paul S Amieux, et al.
Frontiers in Bioscience (Landmark Edition)|June 11, 2013
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinAndrew J Cowan, George S Laszlo, Elihu H Estey, et al.
Journal of Cell Science|November 29, 2013
Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformationAnjali Teckchandani, George S Laszlo, Sergi Simó, et al.
British Journal of Haematology|February 5, 2020
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicityColin D Godwin, Olivia M Bates, Eliotte E Garling, et al.
Haematologica|August 18, 2018
Relationship between CD33 expression, splicing polymorphism, and <i>in vitro</i> cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330George S Laszlo, Mary E Beddoe, Colin D Godwin, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
The Journal of Biological Chemistry|May 24, 2003
Src family kinase-independent signal transduction and gene induction by leukemia inhibitory factorGeorge S Laszlo, Neil M Nathanson
Current Biology : CB|January 17, 2009
Restriction of Src activity by Cullin-5George S Laszlo, Jonathan A Cooper
Journal of Neurochemistry|July 16, 2008
Transregulation of leukemia inhibitory [corrected] factor receptor expression and function by growth factors in neuroblastoma cellsMartha D Port, George S Laszlo, Neil M Nathanson
Blood Reviews|May 10, 2014
The past and future of CD33 as therapeutic target in acute myeloid leukemiaGeorge S Laszlo, Elihu H Estey, Roland B Walter
Biochimica Et Biophysica Acta|July 23, 2005
Calmodulin-dependent protein kinases phosphorylate gp130 at the serine-based dileucine internalization motifRobin M Gibson, George S Laszlo, Neil M Nathanson
Journal of Neurochemistry|June 28, 2006
Multiple promoter elements required for leukemia inhibitory factor-stimulated M2 muscarinic acetylcholine receptor promoter activityGeorge S Laszlo, Marc L Rosoff, Paul S Amieux, et al.
Frontiers in Bioscience (Landmark Edition)|June 11, 2013
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinAndrew J Cowan, George S Laszlo, Elihu H Estey, et al.
Journal of Cell Science|November 29, 2013
Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformationAnjali Teckchandani, George S Laszlo, Sergi Simó, et al.
British Journal of Haematology|February 5, 2020
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicityColin D Godwin, Olivia M Bates, Eliotte E Garling, et al.
Haematologica|August 18, 2018
Relationship between CD33 expression, splicing polymorphism, and <i>in vitro</i> cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330George S Laszlo, Mary E Beddoe, Colin D Godwin, et al.
Pageof 5